Quantcast

Industry news that matters to you.  Learn more

Panel Calls for Biomarkers in Routine Clinical AD Diagnosis

Clinicians should try to incorporate biomarker data in their diagnosis of patients with Alzheimer’s disease or conditions potentially leading to it, an ad hoc expert panel recommended.

Levels of beta-amyloid or tau proteins in cerebrospinal fluid (CSF), or data from MRI or PET scans using amyloid-specific tracers, should be part of the differential diagnosis of Alzheimer-related disorders, according to two dozen members of the International Working Group for New Research Criteria for the Diagnosis of Alzheimer’s Disease.

Circadian Granted Key Strategic VEGF-D Patent in USA for Diagnostic Applications

Circadian Technologies has reported that its subsidiary company, Vegenics Limited, has been granted US Patent 7785803 claiming diagnostic kits for the detection of VEGF-D in human samples such as blood.

VEGF-D, a major novel target for cancer and other diseases, has been shown to be a prognostic indicator of survival or disease progression in a number of different cancer types as well as a biomarker for various respiratory diseases.

CROs Join with MJFF for Parkinson’s Biomarker Research

Covance, Parexel and Epitomics are working with the Michael J Fox Foundation for Parkinson’s Research (MJFF) to develop biomarker candidates.

Initiation of the projects is part of efforts by MJFF to progress biomarker research. MJFF said there is “urgent need for an orchestrated, fieldwide strategy to drive tangible progress” in the sector and contract research organisations (CRO) have a role to play in this initiative.

Michael J. Fox Foundation Announces $1.1 Million to Advance Leading Biomarker Candidates for Parkinson’s Disease

The Michael J. Fox Foundation for Parkinson’s Research today announced nearly $1.1 million for projects aimed at advancing the development of leading biomarker candidates for Parkinson’s disease. The discovery and validation of biomarkers is of critical importance to increasing the speed and efficiency of PD therapeutic development, allowing scientists and clinicians to more accurately identify appropriate subjects for clinical studies, measure disease progression and monitor treatment effects in clinical trials.